

Docket No.: 2815-0293PUS1

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Jens LICHTENBERG et al.

Application No.: Not Yet Assigned

Confirmation No.: N/A

Filed: January 25, 2005

Art Unit: N/A

For:

COMPOUNDS USEFUL FOR THE

TREATMENT OF DISEASES RESPONSIVE

TO ANTIANGIOGENETIC THERAPY

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

MS PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement accompanies the new patent application submitted herewith.

Copies of the references on the PTO/SB/08 are not provided.

A concise explanation of relevance of the items listed on form PTO/SB/08 is in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

DT01 Rec'd PCT/FTE 25 JAN 2005

Application No.: Not Yet Assigned

Docket No.: 2815-0293PUS1

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to our Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under § 1.17; particularly, extension of time fees.

Dated: January 25, 2005

GMM/clb

Respectfully submitted,

Gerald M. Murphy, Jr. Registration No.: 28.977

BIRCH, STEWART, KOLASCH & BIRCH, LLP

8110 Gatehouse Rd Suite 100 East

P.O. Box 747

Falls Church, Virginia 22040-0747

(703) 205-8000

Attorney for Applicant

PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known			
		_		Application Number	Not Yet Assigned 22220		
11	IFORMATION	1 DI	SCLOSURE	Filing Date	January 25, 2005		
S	TATEMENT E	3Y /	APPLICANT	First Named Inventor	Jens LICHTENBERG		
				Art Unit	N/A		
	(Use as many she	eets as	s necessary)	Examiner Name	Not Yet Assigned		
Sheet	1	of	1	Attorney Docket Number	2815-0293PUS1		

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		

	FOREIGN PATENT DOCUMENTS								
Examiner	Cite No.1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear				
Initials*		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				T⁰			
	ВА	WO-03/000245-A1	01-03-2003						
	BB	WO-00/24707-A1	05-04-2000						
	BC	WO-98/47879-A1	10-29-1998						
	BD	WO-00/76495-A1	12-21-2000						
	BE	WO-96/25157-A1	08-22-1996						
	BF	WO-99/32436-A1	07-01-1999						

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²		
	CA	SHEN et al., Journal of Physiology (2000), 529-2. pp. 385-394.			
	СВ	MANOLOPOULOS et al., General Pharmacology 34 (2000) pp. 107-116			
	CC	NICHOLL et al., Pflugers Arch - Eur J. Physiol (2002) 443:875-881.			
	CD	BENNEKOU et al., Blood, March 1, 2001, Volume 97, No. 5, pp. 1451-1457.			
•	CE	GAGLIARDI et al., Cancer Chemother Pharmacol (1998) 41: 117-124.			

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	 Date	
Signature	 Considered	

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.